CytomX Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
CTMX$1.980.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $(18,248) | $23,525 |
| Adjustments to reconcile net income to net cash used in operating activities: | ||
| Amortization of intangible assets | 37 | 36 |
| Depreciation and amortization | 214 | 349 |
| Accretion of discounts on short-term investments | (726) | (454) |
| Stock-based compensation expense | 4,706 | 2,008 |
| Non-cash lease expense | 1,132 | 1,081 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | 1,367 | 1,147 |
| Prepaid expenses and other assets | (887) | (1,202) |
| Accounts payable | 67 | (804) |
| Accrued liabilities and other long-term liabilities | (3,599) | (2,106) |
| Deferred revenue | (9,612) | (44,623) |
| Net cash used in operating activities | (25,549) | (21,043) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (119) |
| Purchases of short-term investments | (242,777) | (19,785) |
| Maturities of short-term investments | 50,000 | 50,500 |
| Net cash (used in) provided by investing activities | (192,777) | 30,596 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net issuance cost | 228,351 | — |
| Proceeds from issuance of pre-funded warrants, net issuance cost | 5,855 | — |
| Proceeds from exercise of stock options | 281 | — |
| Net cash provided by financing activities | 234,487 | — |
| Net increase in cash, cash equivalents and restricted cash | 16,161 | 9,553 |
| Cash, cash equivalents and restricted cash, beginning of period | 14,194 | 39,079 |
| Cash, cash equivalents and restricted cash, end of period | $30,355 | $48,632 |
| Supplemental disclosures of noncash financing activities: | ||
| Common stock issuance costs included in accrued liabilities | $780 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.